Skip to content
10-K

Annual Report

GINKGO BIOWORKS HOLDINGS, INC. DNA DNABW

0001628280-25-007819

← back to feed
Filed
Feb 25, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding restated FY 2024 · Dec 31, 2023 50.03M sh
Current Liabilities FY 2024 · Dec 31, 2023 $163.86M
Total Liabilities FY 2024 · Dec 31, 2023 $568.19M
Current Assets FY 2024 · Dec 31, 2023 $1B
Total Assets FY 2024 · Dec 31, 2023 $1.67B
Shares Diluted restated FY 2024 · Dec 31, 2022 42M sh
Capex FY 2024 · Dec 31, 2022 $52.27M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$252.2M
Eps Diluted restated FY 2024 · Dec 31, 2022 −$50.20
Eps Basic restated FY 2024 · Dec 31, 2022 −$50.15
Sga Expense FY 2024 · Dec 31, 2022 $1.43B
Rd Expense FY 2024 · Dec 31, 2022 $1.05B
Net Income FY 2024 · Dec 31, 2022 −$2.1B
Operating Income FY 2024 · Dec 31, 2022 −$2.21B
Revenue FY 2024 · Dec 31, 2022 $477.71M
Cash And Equivalents FY 2024 · Dec 31, 2021 $1.55B